Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of Gadopiclenol in Healthy Subjects and Brain Lesion Patients
NCT03603106Phase 2Completed
- Sponsor
- Guerbet
- Start
- Nov 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gadopiclenol in brain lesion (2 arms), sponsored by Guerbet. Primary endpoints: Maximum Plasma Concentration, Half-Life and 3 more. Started Nov 2013; status: completed.
02
Drugs
gadopiclenol
03
Conditions
brain lesion
Beyond the preview
Go deeper on NCT03603106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603106.